GCG and metabolic dysfunction-associated steatohepatitis: Liraglutide, as an analog of the glucagon-like peptide-1 (GLP-1), is a promising drug candidate which is being assessed in a phase II clinical trial for NASH (Armstrong et al., 2016[4]).